5-溴-6-羟基烟酸乙酯 | 169773-94-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-6-羟基烟酸乙酯
• 中文别名: 6-羟基-5-溴烟酸乙酯
• 英文名称: ethyl 5-bromo-6-hydroxynicotinate
• 英文别名: ethyl 5-bromo-6-oxo-1H-pyridine-3-carboxylate
• CAS: 169773-94-8
• 化学式: C₈H₈BrNO₃
• 分子量: 246.06
• InChiKey: NTQHDRQVVANNHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-溴-6-羟基烟酸乙酯 在 三溴化磷 、 三溴氧磷 作用下， 反应 3.0h， 以86%的产率得到5,6-二溴烟酸乙酯
  参考文献：
  名称：

  New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

  摘要：

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。

  公开号：

  EP2108641A1
• 作为产物：
  描述：

  6-羟基烟酸乙酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以72%的产率得到5-溴-6-羟基烟酸乙酯
  参考文献：
  名称：

  New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

  摘要：

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。

  公开号：

  EP2108641A1

文献信息

• SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
  申请人：Eastwood Paul Robert

  公开号：US20110053936A1

  公开（公告）日：2011-03-03

  The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本公开涉及新的p38丝裂原活化蛋白激酶抑制剂，其具有一般式(I)，其制备方法，其药物组合物以及其使用方法。
• Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors
  申请人：Eastwood Paul Robert

  公开号：US08772288B2

  公开（公告）日：2014-07-08

  The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本公开涉及一种新的p38有丝分裂原活化蛋白激酶的抑制剂，其具有一般式(I)，其制备方法，制药组合物以及使用方法。
• Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines
  作者：Martin H. Bolli、Cyrille Lescop、Magdalena Birker、Ruben de Kanter、Patrick Hess、Christopher Kohl、Oliver Nayler、Markus Rey、Patrick Sieber、Jörg Velker、Thomas Weller、Beat Steiner

  DOI：10.1016/j.ejmech.2016.03.020

  日期：2016.6

  In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P(1) receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P(1) receptor agonists. While the 2-pyridines were clearly more selective against S1PR(3), the corresponding 3- or 4 pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR(1) and S1PR(3), respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats. (C) 2016 Elsevier Masson SAS. All rights reserved.
• A practical synthesis of the 5-chloromethyl-furo[2,3-b]pyridine pharmacophore
  作者：Woo-Baeg Choi、Ioannis N Houpis、Hywyn R.O Churchill、Audrey Molina、Joseph E Lynch、R.P Volante、Paul J Reider、Anthony O King

  DOI：10.1016/0040-4039(95)00850-c

  日期：1995.6

  Synthesis of the furopyridine 2 was accomplished in 52% overall yield from 6-hydroxynicotinic acid (3). The synthesis is highlighted by a Heck coupling of 5 with ethylene followed by an NCS mediated oxidative cyclization and elimination sequence.
• NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
  申请人：Almirall, S.A.

  公开号：EP2280943B1

  公开（公告）日：2013-11-06